Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jocd.15313 | DOI Listing |
J Cosmet Dermatol
September 2023
Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, Tennessee, USA.
J Cosmet Dermatol
September 2022
Gold Skin Care Center and Tennessee Clinical Research Center, Nashville, Tennessee, USA.
Drugs Real World Outcomes
September 2022
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.
Background: CT-P13 is an infliximab biosimilar that was granted market authorization in Switzerland in 2016. Despite the growing literature supporting the equivalence of CT-P13 compared with originator infliximab regarding the efficacy, safety, and immunogenicity and the undeniable cost-saving opportunities, CT-P13 remains widely underused in Switzerland.
Objective: Leaving aside the phenomenon of a low initiation rate, this study aimed to explore the reasons behind the high discontinuation rate observed among the patients taking CT-P13 in a large tertiary hospital in Western Switzerland.
J Cosmet Dermatol
September 2021
Gold Skin Care Center, Tennessee Clinical Research Center, Nashville, TN, USA.
Ann Surg
June 2021
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Objective: The purpose of this study was to measure the efficacy of a novel faculty and resident educational bundle focused on development of faculty-resident behaviors and entrustment in the operating room.
Summary Background Data: As surgical training environments are orienting to entrustable professional activities (EPAs), successful transitions to this model will require significant faculty and resident development. Identifying an effective educational initiative which prepares faculty and residents for optimizing assessment, teaching, learning, and interacting in this model is critical.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!